cells, ANG IV decreases transcellular Na ϩ transport, as measured by PT O 2 consumption rates (23) , and in human kidney cells, ANG IV increases Na ϩ uptake, reflecting decreased Na ϩ efflux (22) . The receptor for ANG IV (AGTRIV) has been identified as insulin-regulated membrane aminopeptidase, also referred to as cystinyl aminopeptidase (EC 3.4.11.3) (1-3, 6, 7, 15) . AGTRIV is expressed in human PT, distal tubules, vascular smooth muscle, and endothelial cells (10, 21, 22) .
Our laboratory, as well as others, reported data suggesting that renal Anpep may be important in salt handling. In the Goldblatt two-kidney, one-clip model of salt-sensitive hypertension, greater membrane-bound Anpep activity is present in the cortex of the nonclipped kidney (43) . We found that Anpep transcript abundance, protein expression, and activity are greater in the kidneys of Dahl salt-resistant (SR/Jr) vs. Dahl salt-sensitive (SS/Jr) and Sprague-Dawley (SD) rat strains (16) . The Anpep gene maps to a reported blood pressure quantitative trait locus in rats and has a functional polymorphism with promoter activity that is preferentially expressed in the Dahl SR/Jr strain vs. the SS/Jr and SD strains (26) . However, a mechanistic link between renal tubule Anpep and Na transporters has not yet been established.
Normal adaptation to high salt occurs through a coordinated reduction in Na ϩ uptake by PT and distal nephrons (for reviews, see Refs. 4, 11) . Na ϩ -K ϩ -ATPase is the preeminent basolateral Na ϩ transporter in PT. Moreover, adaptation to high salt has been directly linked to a reduction in basolateral Na ϩ -K ϩ -ATPase abundance via endocytosis or internalization of the membrane-associated transporter (36, 40, 41) . The present study was performed to investigate Anpep regulation of basolateral Na
MATERIALS AND METHODS

Materials.
The siRNAs to Anpep (5Ј-AATCGGGCACAGAT-CATTAAT-3Ј) and AGTRIV (5Ј-AACCTGAGTCAGGACGTA-AAT-3Ј) were obtained from Qiagen. Rabbit anti-human polyclonal Anpep antibody (Ab) was from Santa Cruz Biotechnology, and monoclonal Na ϩ -K ϩ -ATPase Abs were from Upstate Biotechnology and Santa Cruz Biotechnology. Polyclonal AGTRIV Ab was kindly provided by Dr. P. Pilch, Boston University School of Medicine. Polyclonal NHE-3 Ab was provided by Dr. J. Liu, Medical College of Ohio. Monoclonal NHE-1 Ab was purchased from BD Biosciences. The control overexpression vector, pcDNA3.1D TOPO, and yellow fluorescent expression vector, pIRES-EYFP, were purchased from Invitrogen and Clontech, respectively. ANG IV was purchased from Phoenix Pharmaceuticals (Burlingame, CA). Porcine renal tubular epithelial cells (LLC-PK1 cells) were from ATCC.
Cell culture. For confocal imaging experiments, LLC-PK1 cells were cultured for passages 8-9 in our laboratory and then seeded in transwell plates at a density of 10,000 cells/cm 2 and cultured for 4 days in DMEM 199 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution. For transfection experiments, LLCPK1 cells were cultured in six-well plates at a density of 25,000 cells/cm 2 . Transfections/plasmids. Anpep expression plasmid was generated by cloning PCR-amplified Anpep cDNA into pcDNA3.1 D His TOPO vector. Anpep cDNA was PCR amplified using primers (forward 5Ј-CACCATGGCCAAGGGTTTCTACATTTCC-3Ј; reverse 5Ј-CTA-GCTGT TTTCTGTGAACCACTTGAG-3Ј) and Anpep cDNA template (NM_001150 and gi: 4502094). Transfections with Anpep expression plasmid (2 g) were performed using Lipofectamine 2000 (Invitrogen) as per manufacturer's instructions. In these experiments, a range of siRNA concentrations was tested and the optimal concentration, based on threshold for maximal suppression of basolateral Na ϩ -K ϩ -ATPase abundance, was 2 g per transfection. Trans messenger transfect reagent (Qiagen) was employed for transfection of siRNA-Anpep (2 g) and siRNA-AGTRIV (2 g). Cells were harvested 48 h after transfection with siRNA or Anpep overexpression. Na ϩ -K ϩ -ATPase activity assay. Na ϩ -K ϩ -ATPase activity was determined as the rate of inorganic phosphate released in the presence or absence of ouabain (13, 14, 32) . To prepare membranes for Na ϩ -K ϩ -ATPase activity assay, cells from numbers 5-6 150-mm 2 dishes were washed twice with 5 ml chilled phosphate-free buffer (2.36 M NaCl, 0.54 M NaHCO 3, 0.4 M KCl, and 0.12 M MgCl2scraped in phosphate-free buffer) and centrifuged at 3,000 g for 8 -10 min. The cells were then placed on ice and lysed by dounce homogenization in 2 ml of lysis buffer (1 mM NaHCO 3, 2 mM CaCl2, and 5 mM MgCl2). Cellular lysates were centrifuged at 3,000 g for 1-2 min to remove intact cells, debris, and nuclei. The resulting supernatant was suspended in an equal volume of 1 M NaI, and the mixture was centrifuged at 48,000 g for 25 min. The pellet (membrane fraction) was washed one to two times and suspended in 10 mM Tris and 1 mM EDTA (pH 7.4). Protein concentrations were determined by the Bradford assay and adjusted to 1 mg/ml. The membranes were stored at Ϫ70°C until further use. To measure Na ϩ -K ϩ -ATPase activity, 100-l aliquots of membrane fraction were added to an 800-l reaction mixture (75 mM NaCl, 5 mM KCl, 5 mM MgCl 2, 6 mM NaN 2, 1 mM Na EGTA, 37.5 mM imidazole, 75 mM Tris ⅐ HCl, and 30 mM histidine; pH 7.4) with or without 1 mM ouabain (final volume ϭ 1 ml) and preincubated for 5 min in a water bath at 37°C. Reactions were initiated by adding Tris ATP (4 mM) and were terminated after 15 min of incubation at 37°C by adding 50 l of 50% TCA. For determination of ouabain-insensitive ATPase activity, NaCl and KCl were omitted from reaction mixtures containing ouabain. To quantify the amount of phosphate produced, 1 ml of coloring reagent (10% ammonium molybdate in 10 N sulfuric acid ϩ ferrous sulfate) was added to the reaction mixture. The mixture was then combined thoroughly and centrifuged at 3,000 g for 10 min. Formation of phosphomolybdate was determined spectrophotometrically at 740 nm, 
ATPase abundance in whole cell extracts (n ϭ 3). E: NHE-1 (n ϭ 3). F: NHE-3 abundance (n ϭ 3). *P Ͻ 0.01 vs. controls. against a standard curve prepared from K2HPO4. Na ϩ -K ϩ -ATPase activity was estimated as the difference between total ATPase activity and ouabain-insensitive ATPase activity and was expressed as nanomoles of phosphate produced per milligram of protein per minute.
Confocal microscopy. Cells were fixed in 2% paraformaldehyde and permeabilized with 0.08% saponin in phosphate-buffered saline for 10 min. Slides were then successively incubated with anti-Na ϩ -K ϩ -ATPase ␣-monoclonal primary Ab (1:2,000 dilution) for 1 h and with FITC-conjugated anti-mouse secondary antibody. Confocal images were obtained using Zeiss laser-scanning confocal microscope LSM 510 META.
Surface biotinylations. Biotinylations were performed with EZLink Sulfo-NHS-SS-Biotin (Pierce) in a sucrose-containing borate buffer (pH 9.0), as previously described (18) . Cells were grown to 85-90% confluence in six-well transwell plates before transfection. Biotinylations were performed when the cells were completely confluent. The biotinylation buffer was placed in the bottom chamber of the transwell plates, and plates were incubated for 1.5 h at 4°C. Biotinylated proteins were immunoprecipitated from total cell extracts with streptavidin agarose, released by incubation in 10 mM dithiothreitol, reconstituted in Laemmli buffer, and subjected to SDS-PAGE and Western analysis.
Western analysis. Protein samples were prepared in lysis buffer (50 mM Tris ⅐ HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.25% sodium deoxycholate, 1% NP-40, and protease inhibitor cocktail), and equal amounts of protein were separated by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with the indicated primary Abs and incubated with appropriate horseradish peroxidase-conjugated secondary Ab. Chemiluminescence was detected using ECL Western blotting detection reagents (Amersham). Signal was normalized to total cell protein. The bands were quantified by NIH image analysis. Band saturation was avoided by using the shortest exposure time necessary to detect signals and comparing results with two different submaximal exposure times.
Statistical analysis. Comparisons were made by one-way ANOVA followed by the Tukey-Kramer multiple comparisons test. Data are expressed as means Ϯ SD. P Ͻ 0.05 was accepted as significant. (Fig. 1A) . Both Na ϩ -K ϩ -ATPase activity and basolateral Na ϩ -K ϩ -ATPase abundance, as measured by surface biotinylation, were reduced by ϳ70% with Anpep OE (P Ͻ 0.05; Fig. 1, B-C) . Consistent with these results, surface staining for Na ϩ -K ϩ -ATPase ␣-subunit was reduced in confocal imaging (Fig. 2) . In a complementary set of experiments, the effect of siRNAmediated knockdown of Anpep on basolateral Na ϩ -K ϩ -ATPase abundance and Na ϩ -K ϩ -ATPase activity was examined. Endogenous Anpep protein levels were reduced by 50% in siRNA-transfected cells (Fig. 1) . Conversely, both biotinylated Na ϩ -K ϩ -ATPase abundance and Na ϩ -K ϩ -ATPase activity approximately doubled (Fig. 1, B and C) .
RESULTS
Anpep negatively regulates Na
The abundance of whole cell Na ϩ -K ϩ -ATPase, the apical transporter NHE3, and basolateral transporter NHE1 (Fig. 1, D , E, and F, respectively) were also measured by Western analysis. The abundance of these proteins was similar with Anpep overexpression and Anpep siRNA, suggesting that NHE3 and NHE1 are not regulated, at least at the level of expression, by Anpep.
Anpep signaling requires AGTRIV. To investigate the ANG IV dependence of Anpep signaling, we examined the effect of AGTRIV siRNA on the basolateral abundance and activity of Na ϩ -K ϩ -ATPase. Forty-eight hours after transfection with AGTRIV siRNA, AGTRIV protein levels were reduced by 2.5-fold. This was accompanied by an approximate twofold increase in the basolateral Na ϩ -K ϩ -ATPase abundance (P Ͻ 0.05) and activity (P Ͻ 0.05; Fig. 3) . In a second set of experiments, the effect of AGTRIV knockdown on regulation of Na ϩ -K ϩ -ATPase by Anpep was examined. Cells were first transfected with AGTRIV siRNA and 24 h later transfected again with Anpep expression vector. Inhibition of AGTRIV Fig. 3 . Effect of siRNA-mediated AGTRIV knockdown on regulation of basolateral Na ϩ -K ϩ -ATPase by Anpep in LLC-PK1 cells. Cells were transfected with AGTRIV siRNA ϩ Anpep expression plasmid (Anpep OE), scrambled siRNA ϩ vector (OE vector; controls). A: Na ϩ -K ϩ -ATPase activity in membrane protein extracts (n ϭ 4). B: biotinylated Na ϩ -K ϩ -ATPase in cotransfected LLC-PK1 cells; representative immunoblots for AGTRIV and actin in whole cell extracts (top 2 rows) and for biotinylated Na ϩ -K ϩ -ATPase (row 3; n ϭ 4). *P Ͻ 0.05. expression by siRNA was confirmed by Western analysis (Fig.  3B) . AGTRIV knockdown relieved the negative effect of Anpep overexpression on Na ϩ -K ϩ -ATPase, as seen by approximately threefold greater basolateral Na ϩ -K ϩ -ATPase abundance and Na ϩ -K ϩ -ATPase activity in AGTRIV siRNAAnpep OE cotransfected cells vs. scrambled siRNA-Anpep OE cotransfected counterparts (P Ͻ 0.05; Fig. 3) . Thus, Anpep regulation of Na ϩ -K ϩ -ATPase requires AGTRIV expression. ANG IV negatively regulates Na ϩ -K ϩ -ATPase. Since ANG IV is formed by Anpep (37, 48) , we examined the effect of ANG IV on Na ϩ -K ϩ -ATPase in LLC-PK1 cells. ANG IV treatment (10 nM, 30 min and 12 h) reduced Na ϩ -K ϩ -ATPase activity by approximately three-to fourfold (Fig. 4A , P Ͻ 0.05). Biotinylated Na ϩ -K ϩ -ATPase was reduced by approximately fourfold (P Ͻ 0.05) (Fig. 4B ) and surface straining in confocal imaging decreased (Fig. 2, ANG IV) . Whole cell (Fig.  4C ) Na ϩ -K ϩ -ATPase abundance was not decreased.
DISCUSSION
The aim of this study was to relate Anpep to regulation of Na ϩ handling in PT. We demonstrated that Anpep reduces basolateral Na ϩ -K ϩ -ATPase levels and activity of Na ϩ -K ϩ -ATPase. Immunohistochemical data suggest that these effects may be due to membrane trafficking of Na (31, 44) and the effect of Anpep inhibitors to reduced metabolism and increased signaling by these substrates. Our study is the first, to our knowledge, to link signaling by Anpep to a product, i.e., ANG IV, rather than substrate.
The reduction in basolateral Na ϩ -K ϩ -ATPase abundance and Na ϩ -K ϩ -ATPase activity associated with Anpep overexpression was inhibited by blocking AGTRIV expression with specific siRNA, suggesting signaling occurs through an ANG IV-dependent mechanism. This is the first time that this pluripotent signaling molecule has been implicated in intracellular signaling in LLC-PK1 cells. ANG IV has been reported to inhibit energy-dependent Na transport in PT cell lines (8) and also to inhibit Na ϩ uptake in a manner similar to ouabain (21). Our results suggest that inhibition of Na transport is due, at least in part, to reduced Na ϩ -K ϩ -ATPase. If Anpep synthesizes ANG IV in cultured LLC-PK1 cells, this suggests of that either local renin-angiotensin system (RAS) signaling is present in renal epithelial cells or that the culture media, including fetal bovine serum, provides substrates. The existence of principal components of RAS, including ANG II, is well established in a variety of tissues (27, 39, 45) . Substrates for ANG IV formation include ANG III and ANG I (R-V-Y-I-H-P-F-H-L; Angiotensin 2-10) which is converted to ANG IV by Anpep and carboxypeptidase or angiotensin. The in vivo utilization of these substrates is not known. However, our results suggest that if signaling is through ANG IV formation that the process is not substrate limited since Anpep overexpression increases signaling.
Although AGTRIV has been identified as a receptor for ANG IV, its role has remained controversial since ANG IV also has a low affinity for AT1, AT2, and ANG-(1-7) (5, 17, 30, 49) receptors. The finding that the effect of ANG IV on Na ϩ -K ϩ -ATPase is blocked by AGTRIV siRNA provides unique supportive evidence that this signaling occurs via AGTRIV, but does not exclude simultaneous effects on other receptors. A rigorous investigation of the mechanism(s) underlying selectivity for specific receptors under different conditions will require measurements of local ANG IV concentration and receptors. There is also the possibility that expression of AGTRIV is regulated and plays an independent role in Anpep signaling. For instance, it has been shown that AGTRIV receptor binding is greater in the renal outer medulla of WistarKyoto rats than of spontaneously hypertensive rats (19) .
The reduction in biotinylated Na ϩ -K ϩ -ATPase induced by Anpep is not accompanied by a decrease in whole cell Na ϩ -K ϩ -ATPase abundance. This is consistent with the report by Choukroun et al. (9) in which surface expression, also measured by biotinylation, of Na ϩ -K ϩ -ATPase in cultured renal epithelial cells was reduced by phospholipase A 2 while total cell Na ϩ -K ϩ -ATPase was unaffected. This was interpreted as an indication that trafficking of Na ϩ -K ϩ -ATPase was primarily being regulated in this setting. Determination of regulation of intracellular Na ϩ -K ϩ -ATPase transport and synthesis by Anpep will further understanding of regulation of basolateral Na ϩ -K ϩ -ATPase by Anpep. The results also raise the intriguing possibility that two zinc-dependent aminopeptidases, AGTRIV and Anpep, may regulate Na ϩ -K ϩ -ATPase in cells. Although both aminopeptidases metabolize ANG III and ANG IV and are inhibited by ANG IV, they are distinct enzymes that likely serve nonoverlapping functions. AGTRIV is insulin regulated and is present in GLUT4-containing vesicles. AGTRIV, but not Anpep, has been linked to activation of Erk1/2 (29) , which may mediate endocytosis of basolateral Na ϩ -K ϩ -ATPase. AGTRIV also can activate NF-B and related proinflammatory genes in vascular smooth muscle cells (15) . AGTRIV is the only membrane aminopeptidase reported to cleave vasopressin (24) . The results also highlight the possibility that Anpep may not only signal through regulation of metabolism of substrates but also through the synthesis of products, e.g., ANG IV.
There is the possibility that other apical and basolateral transporters may be regulated directly or indirectly by Anpep and ANG IV. Some agents, e.g., PTH, which redistributes apical NHE3 and NaPi2 transporters while inhibiting basolateral Na ϩ -K ϩ -ATPase (50), and captopril, which redistributes multiple membrane-associated proteins (28) , regulate more than one PT transporter. Some changes in transporters may be secondary to others, e.g., basolateral Na ϩ -K ϩ -ATPase is known to regulate the expression and activity apical transporters, including NHE3 (38) and, vice versa, it is possible that apical transporters modulate basolateral transporters. To more fully understand regulation by Anpep of Na ϩ -K ϩ -ATPase will require insight into effects on apical and other basolateral transporters. As a first step to addressing this, we measured NHE3 and NHE1 protein abundance. A significant change abundance of neither was detected with Anpep overexpression nor siRNA to Anpep, suggesting that these transporters are not regulated by Anpep. Clearly, further studies are needed to critically investigate regulation of Na transport by Anpep.
The present findings demonstrate that Anpep regulates basolateral Na ϩ -K ϩ -ATPase abundance and activity in LLC-PK1 cells via a novel signaling pathway that requires AGTRIV. Because renal Anpep expression is greater in the Dahl SR/Jr rat than in the Dahl SS/Jr rat, Anpep may contribute to reduction of basolateral Na ϩ -K ϩ -ATPase in the SR/Jr strain and adaptation to high salt (16, 26, 33, 34) . Inappropriately low levels of renal tubule Anpep may thus contribute to salt sensitivity. The in vivo relationship between Anpep and mediators of salt adaptation such as nitric oxide (20) , dopamine (12, 33) , natriuretic peptides (46) , and marinobufagenin (41) will be necessary to understand the role of Anpep and ANG IV/AGTRIV in blood pressure regulation. Nevertheless, the present results raise the possibility that Anpep and ANG IV/AGTRIV agonists are novel therapeutic targets and agents, respectively, for salt-dependent hypertension.
